+ |
125-L-serine-2-133-interleukin 2 (human reduced) | up-regulates activity
chemical activation
|
IL2RB |
0.8 |
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-259389 |
|
|
Homo sapiens |
|
pmid |
sentence |
18031103 |
Aldesleukin (recombinant IL-2) has similar pharmacodynamic properties to endogenous IL-2 and, when administered to patients with cancer, stimulates the antitumour immune response. |
|
Publications: |
1 |
Organism: |
Homo Sapiens |
+ |
125-L-serine-2-133-interleukin 2 (human reduced) | up-regulates activity
chemical activation
|
IL2RG |
0.8 |
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-259390 |
|
|
Homo sapiens |
|
pmid |
sentence |
18031103 |
Aldesleukin (recombinant IL-2) has similar pharmacodynamic properties to endogenous IL-2 and, when administered to patients with cancer, stimulates the antitumour immune response. |
|
Publications: |
1 |
Organism: |
Homo Sapiens |
+ |
125-L-serine-2-133-interleukin 2 (human reduced) | up-regulates activity
chemical activation
|
IL2RA |
0.8 |
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-259388 |
|
|
Homo sapiens |
|
pmid |
sentence |
18031103 |
Aldesleukin (recombinant IL-2) has similar pharmacodynamic properties to endogenous IL-2 and, when administered to patients with cancer, stimulates the antitumour immune response. |
|
Publications: |
1 |
Organism: |
Homo Sapiens |